Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction.
Julian MüllerDaniela A FerraroUrs J MuehlematterHelena I Garcia SchülerSarah KedziaDaniel EberliMatthias GuckenbergerStephanie G C KroezeTullio SulserDaniel M SchmidAurelius OmlinAlexander MüllerThomas ZilliHubert JohnHelmut KranzbuehlerPhilipp A KaufmannGustav K von SchulthessIrene Andrea BurgerPublished in: European journal of nuclear medicine and molecular imaging (2018)
The high rate of recurrence detection by PSMA PET was confirmed and PSMA PET led to a change in management in 60% of patients. Focal therapy for PSMA-positive lesions is a promising approach with complete responses in 45% of patients.